Patient characteristics
| Characteristics . | Training cohort (n = 86) . | Validation cohort (n = 64) . | P . |
|---|---|---|---|
| Sex, male/female, n | 44/42 | 31/33 | .512 |
| Age, median (range), y | 71 (24-90) | 74 (33-86) | .019 |
| ECOG performance status | <.01 | ||
| 0 or 1 | 81 (94) | 45 (70) | |
| ≥2 | 5 (6) | 19 (30) | |
| Ann Arbor stage | <.01 | ||
| I or II | 54 (63) | 12 (19) | |
| III | 11 (13) | 13 (20) | |
| IV | 21 (24) | 39 (61) | |
| Extranodal sites | .281 | ||
| 0 | 60 (70) | 22 (34) | |
| ≥1 | 26 (30) | 42 (66) | |
| Bone marrow involvement | .541 | ||
| Yes | 10 (12) | 11 (17) | |
| No | 76 (88) | 53 (83) | |
| B symptoms | .330 | ||
| Yes | 12 (14) | 29 (58) | |
| No | 74 (86) | 35 (42) | |
| LDH | .285 | ||
| ≤Normal | 45 (52) | 21 (33) | |
| >Normal | 41 (48) | 43 (67) | |
| TMTV, cm3 | .411 | ||
| Median (range) | 167.23 (4.61-5445.50) | 236.32 (76.62-677.09) | |
| ≥150 | 44 (51) | 26 (41) | |
| ≥150 | 42 (49) | 38 (59) | |
| MH (AUC-CSH) | 1.000 | ||
| Median (range) | 0.48 (0.24-0.93) | 0.49 (0.33-0.75) | |
| Low (>0.48) | 43 (50) | 32 (50) | |
| High (≤0.48) | 43 (50) | 32 (50) | |
| NCCN-IPI | .014 | ||
| Low or low-intermediate | 47 (55) | 15 (24) | |
| High-intermediate | 33 (38) | 20 (31) | |
| High | 6 (7) | 29 (45) | |
| Treatment | <.01 | ||
| R-CHOP | 81 (94) | 27(42) | |
| R-THP-COP | 5 (6) | 36 (56) | |
| R-CVP | 0 (0) | 1 (2) | |
| Response | |||
| CR | 67 (78) | 41 (64) | .069 |
| PR | 4 (5) | 8 (13) | .126 |
| SD | 11 (12) | 9 (14) | .814 |
| PD | 4 (5) | 6 (9) | .326 |
| Follow-up, mo | |||
| Median (range) | 33.1 (3.6-97.3) | 32.8 (1.4-111.5) |
| Characteristics . | Training cohort (n = 86) . | Validation cohort (n = 64) . | P . |
|---|---|---|---|
| Sex, male/female, n | 44/42 | 31/33 | .512 |
| Age, median (range), y | 71 (24-90) | 74 (33-86) | .019 |
| ECOG performance status | <.01 | ||
| 0 or 1 | 81 (94) | 45 (70) | |
| ≥2 | 5 (6) | 19 (30) | |
| Ann Arbor stage | <.01 | ||
| I or II | 54 (63) | 12 (19) | |
| III | 11 (13) | 13 (20) | |
| IV | 21 (24) | 39 (61) | |
| Extranodal sites | .281 | ||
| 0 | 60 (70) | 22 (34) | |
| ≥1 | 26 (30) | 42 (66) | |
| Bone marrow involvement | .541 | ||
| Yes | 10 (12) | 11 (17) | |
| No | 76 (88) | 53 (83) | |
| B symptoms | .330 | ||
| Yes | 12 (14) | 29 (58) | |
| No | 74 (86) | 35 (42) | |
| LDH | .285 | ||
| ≤Normal | 45 (52) | 21 (33) | |
| >Normal | 41 (48) | 43 (67) | |
| TMTV, cm3 | .411 | ||
| Median (range) | 167.23 (4.61-5445.50) | 236.32 (76.62-677.09) | |
| ≥150 | 44 (51) | 26 (41) | |
| ≥150 | 42 (49) | 38 (59) | |
| MH (AUC-CSH) | 1.000 | ||
| Median (range) | 0.48 (0.24-0.93) | 0.49 (0.33-0.75) | |
| Low (>0.48) | 43 (50) | 32 (50) | |
| High (≤0.48) | 43 (50) | 32 (50) | |
| NCCN-IPI | .014 | ||
| Low or low-intermediate | 47 (55) | 15 (24) | |
| High-intermediate | 33 (38) | 20 (31) | |
| High | 6 (7) | 29 (45) | |
| Treatment | <.01 | ||
| R-CHOP | 81 (94) | 27(42) | |
| R-THP-COP | 5 (6) | 36 (56) | |
| R-CVP | 0 (0) | 1 (2) | |
| Response | |||
| CR | 67 (78) | 41 (64) | .069 |
| PR | 4 (5) | 8 (13) | .126 |
| SD | 11 (12) | 9 (14) | .814 |
| PD | 4 (5) | 6 (9) | .326 |
| Follow-up, mo | |||
| Median (range) | 33.1 (3.6-97.3) | 32.8 (1.4-111.5) |
Unless otherwise noted, data are n (%).
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD, progressive disease; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisolone; R-THP-COP, rituximab, therarubicin, cyclophosphamide, vincristine, and prednisolone; SD, stable disease.